Literature DB >> 21554992

The relative efficiency of time-to-threshold and rate of change in longitudinal data.

M C Donohue1, A C Gamst, R G Thomas, R Xu, L Beckett, R C Petersen, M W Weiner, P Aisen.   

Abstract

Randomized, placebo-controlled trials often use time-to-event as the primary endpoint, even when a continuous measure of disease severity is available. We compare the power to detect a treatment effect using either rate of change, as estimated by linear models of longitudinal continuous data, or time-to-event estimated by Cox proportional hazards models. We propose an analytic inflation factor for comparing the two types of analyses assuming that the time-to-event can be expressed as a time-to-threshold of the continuous measure. We conduct simulations based on a publicly available Alzheimer's disease data set in which the time-to-event is algorithmically defined based on a battery of assessments. A Cox proportional hazards model of the time-to-event endpoint is compared to a linear model of a single assessment from the battery. The simulations also explore the impact of baseline covariates in either analysis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21554992      PMCID: PMC3148349          DOI: 10.1016/j.cct.2011.04.007

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  18 in total

1.  Continuous, categorical, and time to event cocaine use outcome variables: degree of intercorrelation and sensitivity to treatment group differences.

Authors:  J R McKay; A I Alterman; J M Koppenhaver; F D Mulvaney; G B Bovasso; K Ward
Journal:  Drug Alcohol Depend       Date:  2001-03-01       Impact factor: 4.492

2.  Multivariate longitudinal models for complex change processes.

Authors:  L A Beckett; D J Tancredi; R S Wilson
Journal:  Stat Med       Date:  2004-01-30       Impact factor: 2.373

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Sample-size formula for the proportional-hazards regression model.

Authors:  D A Schoenfeld
Journal:  Biometrics       Date:  1983-06       Impact factor: 2.571

5.  Measurement of functional activities in older adults in the community.

Authors:  R I Pfeffer; T T Kurosaki; C H Harrah; J M Chance; S Filos
Journal:  J Gerontol       Date:  1982-05

6.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

7.  Vitamin E and donepezil for the treatment of mild cognitive impairment.

Authors:  Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal
Journal:  N Engl J Med       Date:  2005-04-13       Impact factor: 91.245

8.  A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.

Authors:  Leon J Thal; Steven H Ferris; Louis Kirby; Gilbert A Block; Christopher R Lines; Eric Yuen; Christopher Assaid; Michael L Nessly; Barbara A Norman; Christine C Baranak; Scott A Reines
Journal:  Neuropsychopharmacology       Date:  2005-06       Impact factor: 7.853

9.  Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.

Authors:  Jennifer J Anderson; James A Bolognese; David T Felson
Journal:  Arthritis Rheum       Date:  2003-11

10.  A new rating scale for Alzheimer's disease.

Authors:  W G Rosen; R C Mohs; K L Davis
Journal:  Am J Psychiatry       Date:  1984-11       Impact factor: 18.112

View more
  14 in total

1.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

2.  Is there a rationale for including only patients already being treated with acetylcholinesterase inhibitors in a prodromal AD trial?

Authors:  M Grundman; E Yang; A Dibernardo
Journal:  J Nutr Health Aging       Date:  2012-04       Impact factor: 4.075

Review 3.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

4.  Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease.

Authors:  Chengjie Xiong; Hua Weng; David A Bennett; Patricia A Boyle; Raj C Shah; Scot Fague; Charles B Hall; Richard B Lipton; John C Morris
Journal:  Neuroepidemiology       Date:  2014-11-05       Impact factor: 3.282

5.  IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.

Authors:  Carlton D Dampier; Wally R Smith; Carrie G Wager; Hae-Young Kim; Margaret C Bell; Scott T Miller; Debra L Weiner; Caterina P Minniti; Lakshmanan Krishnamurti; Kenneth I Ataga; James R Eckman; Lewis L Hsu; Donna McClish; Sonja M McKinlay; Robert Molokie; Ifeyinwa Osunkwo; Kim Smith-Whitley; Marilyn J Telen
Journal:  Clin Trials       Date:  2013-04       Impact factor: 2.486

6.  Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes.

Authors:  Carlton D Dampier; Carrie G Wager; Ryan Harrison; Lewis L Hsu; Caterina P Minniti; Wally R Smith
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

7.  Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.

Authors:  P S Aisen
Journal:  J Prev Alzheimers Dis       Date:  2015

8.  The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.

Authors:  Nandini Raghavan; Mahesh N Samtani; Michael Farnum; Eric Yang; Gerald Novak; Michael Grundman; Vaibhav Narayan; Allitia DiBernardo
Journal:  Alzheimers Dement       Date:  2012-11-02       Impact factor: 21.566

Review 9.  The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Jennifer Salazar; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2016-12-05       Impact factor: 21.566

Review 10.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Li Shen; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-07       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.